Vivo Capital LLC Acquires 98,934 Shares of CymaBay Therapeutics Inc (NASDAQ:CBAY)
Vivo Capital LLC grew its position in CymaBay Therapeutics Inc (NASDAQ:CBAY) by 4.8% during the second quarter, HoldingsChannel reports. The firm owned 2,154,934 shares of the biopharmaceutical company’s stock after buying an additional 98,934 shares during the quarter. CymaBay Therapeutics comprises approximately 1.4% of Vivo Capital LLC’s holdings, making the stock its 20th biggest position. Vivo Capital LLC’s holdings in CymaBay Therapeutics were worth $15,429,000 as of its most recent SEC filing.
Several other large investors have also recently added to or reduced their stakes in CBAY. Bank of Montreal Can grew its stake in shares of CymaBay Therapeutics by 1,372.0% in the second quarter. Bank of Montreal Can now owns 6,771 shares of the biopharmaceutical company’s stock worth $48,000 after acquiring an additional 6,311 shares during the last quarter. Aperio Group LLC bought a new position in shares of CymaBay Therapeutics in the second quarter valued at about $104,000. BNP Paribas Arbitrage SA bought a new position in shares of CymaBay Therapeutics in the first quarter valued at about $165,000. National Asset Management Inc. bought a new stake in CymaBay Therapeutics during the 2nd quarter worth about $165,000. Finally, Parametric Portfolio Associates LLC raised its holdings in CymaBay Therapeutics by 19.7% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 29,838 shares of the biopharmaceutical company’s stock worth $214,000 after purchasing an additional 4,920 shares during the last quarter. 98.67% of the stock is currently owned by institutional investors.
CBAY has been the subject of a number of recent analyst reports. BidaskClub cut CymaBay Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, July 30th. Piper Jaffray Companies reduced their price target on CymaBay Therapeutics from $30.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday, June 11th. Citigroup reduced their price target on CymaBay Therapeutics from $21.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, June 13th. Oppenheimer set a $12.00 price objective on CymaBay Therapeutics and gave the company a “buy” rating in a report on Tuesday, June 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $12.00 price objective (down previously from $24.00) on shares of CymaBay Therapeutics in a report on Wednesday, June 12th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $14.09.
CymaBay Therapeutics (NASDAQ:CBAY) last announced its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.35) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.02. On average, equities research analysts anticipate that CymaBay Therapeutics Inc will post -1.47 EPS for the current fiscal year.
About CymaBay Therapeutics
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.
Featured Article: How to identify percentage decliners
Want to see what other hedge funds are holding CBAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CymaBay Therapeutics Inc (NASDAQ:CBAY).
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.